The Global Epidemic (Q Abdool Karim, Section Editor)

Current HIV/AIDS Reports

, Volume 10, Issue 2, pp 142-151

First online:

Use of Antiretrovirals for HIV Prevention: What Do We Know and What Don’t We Know?

  • Jared M. BaetenAffiliated withDepartments of Global Health, Medicine, and Epidemiology, University of Washington Email author 
  • , Robert GrantAffiliated withGladstone Institutes, University of California, San Francisco

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Pre-exposure prophylaxis (PrEP), in which HIV uninfected persons with ongoing HIV risk use antiretroviral medications as chemoprophylaxis against sexual HIV acquisition, is a promising new HIV prevention strategy. Proof-of-concept that PrEP, as oral or vaginal topical tenofovir-based products, protects against sexual HIV acquisition has been demonstrated in clinical trials conducted among men who have sex with men and heterosexual men and women. The degree of HIV protection in these trials was strongly related to the level of adherence to PrEP. Many questions are yet unanswered – including how to motivate uptake of and sustain adherence to PrEP for HIV prevention, how much PrEP use is enough to achieve HIV protection, and the potential of “next-generation” PrEP agents to improve on this effective technology.


Antiretroviral medications Chemoprophylaxis Global epidemic HIV/AIDS HIV prevention Pre-exposure prophylaxis (PrEP) Sexual HIV transmission